Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

DGXBullishIndustry Newsnews

High materiality7/10

Quest Diagnostics and Waters Expand At-Home HPV Testing Network Starting 2027

Oct 20, 2026, 8:17 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Higher disease-screening volumes typically drive lab utilization and revenue for large reference labs like DGX; multi-year ramp begins 2027 with Waters/BD+Quest backbone; incremental volume and payer coverage could lift margins over time.

AI summary

What happened, with direct paths to the underlying reporting

Quest Diagnostics and Waters announce a collaboration to broaden access to the FDA-cleared Onclarity Self-Collection HPV kit, expanding into clinical, health-plan, and consumer channels by 2027. The kit offers extended genotyping and supports ASCCP Enduring Risk-Based Guidelines, potentially boosting Quest's lab volumes as at-home screening reduces barriers and grows the screening population.

Quest Diagnostics and Waters expand at-home HPV testing nationwide from 2027. Across clinician, health plan, and consumer channels.
First FDA-approved HPV test with extended genotyping; supports all ASCCP guidelines. Enhances risk-based management.
Quest reaches one in three American adults. Footprint spans roughly half of U.S. hospitals.
Approximately 24 million under-screened individuals; 14,000 new cervical cancer cases annually.
Beginning in 2027, Quest expands access via clinician, plan, and consumer channels.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.